Drug persistence in patients with rheumatic and musculoskeletal diseases during a major economic crisis: results from a nationwide cross-sectional online survey
Rheumatology International · 2024
DOI: 10.1007/s00296-023-05526-9 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Rheumatology International, 2024. Verfasst von Serena Asmar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hotel Dieu de France Hospital, Beirut, Lebanon. serenasmar98@gmail.com. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Biological Products, Antirheumatic Agents, Musculoskeletal Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
To evaluate the drug persistence in patients with rheumatic and musculoskeletal diseases (RMDs) during the current economic crisis in Lebanon and to estimate predictors of persistence. A nationwide multicentric cross-sectional study using an online questionnaire was conducted in Lebanon with patients with chronic inflammatory rheumatic diseases (CIRDs) and non-inflammatory RMDs controls between July and October 2022. Disease-modifying antirheumatic drugs (DMARDs) were categorized as conventional synthetic (cs), biological (b), subcutaneous (SC) or intravenous (IV), and targeted synthetic (ts). Persistence was defined as "number of tablets or injections taken during the past month versus prescribed". The percentage of patients who discontinued or changed treatment due to cost or non-availability was reported. Factors associated with persistence were identified using multivariable linear regression. The study included 317 patients with RMDs (286 CIRDs); mean age 49.5 years, 68% females, 58% reporting currently low economic level. Persistence at one month was low for tsDMARDs (36%) and bDMARDs (SC55%, IV63%), and acceptable for csDMARDs (88%). A persistence ≥80% was found in 23.3% of patients on tsDMARDs, 42.9% on SC bDMARDs, 45.0% on IV bDMARDs, and 74.7% on csDMARDs. During the past 6 months, 55.8% of CIRD patients discontinued or changed treatment due to non-availability (45.3%) or cost (21.2%). Persistence was positively associated with finding alternative sources such as buying abroad (36%), depending on friends or families abroad (20%), charities (10%), and negatively associated with unemployment and low financial status. Persistence was significantly compromised for essential antirheumatic drugs and was mostly driven by treatment unavailability and cost.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hotel Dieu de France Hospital, Beirut, Lebanon. serenasmar98@gmail.com.
- Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon. serenasmar98@gmail.com.
- Monla Hospital, Tripoli, Lebanon.
- Ain Wazein Medical Village, Chouf, Lebanon.
- American University of Beirut Medical Center, Beirut, Lebanon.
- Clemenceau Medical Center, Beirut, Lebanon.
ORCID-Profile: Serena Asmar, Mohamad Ali Rida, Krystel Aouad, Nelly Ziade
Zitieren
APA
Asmar, S., Messaykeh, J., Hilal, N., Rida, M. A., Mroue, K., Aouad, K., Minkara, F., Hajjar, A., & Ziade, N. (2024). Drug persistence in patients with rheumatic and musculoskeletal diseases during a major economic crisis: results from a nationwide cross-sectional online survey. Rheumatology International. https://doi.org/10.1007/s00296-023-05526-9
Vancouver
Asmar S, Messaykeh J, Hilal N, Rida MA, Mroue K, Aouad K, et al. Drug persistence in patients with rheumatic and musculoskeletal diseases during a major economic crisis: results from a nationwide cross-sectional online survey. Rheumatology International. 2024. doi:10.1007/s00296-023-05526-9
BibTeX
@article{Asmar2024,
author = {Asmar, Serena and Messaykeh, Jamil and Hilal, Nadeen and Rida, Mohamad Ali and Mroue, Kamel and Aouad, Krystel and Minkara, Fouad and Hajjar, Arlette and Ziade, Nelly},
title = {Drug persistence in patients with rheumatic and musculoskeletal diseases during a major economic crisis: results from a nationwide cross-sectional online survey},
journal = {Rheumatology International},
year = {2024},
doi = {10.1007/s00296-023-05526-9}
}
EUVIMED